Axsome Therapeutics, Inc.AXSM
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · axsome.com
Axsome Therapeutics, Inc. is a New York-based commercial-stage biopharmaceutical company focused on central nervous system disorders. Its marketed products include AUVELITY (major depressive disorder and agitation associated with Alzheimer's dementia), SUNOSI (excessive daytime sleepiness) and SYMBRAVO (migraine), alongside multiple late-stage programs including AXS-05 in smoking cessation.
Key ratios
FCF / Sales
-9.3%TTM
2025
-14.7%2024
-33.4%2023
-53.8%
Net margin
-24.7%TTM
2025
-28.7%2024
-74.5%2023
-88.4%
ROA
-16.8%2025
2024
-27.3%2023
-24.9%
ROE
-252.1%2025
2024
-231.6%2023
-159.2%
Revenue growth
56.9%TTM
2025
65.6%2024
42.5%2023
440.8%
Recent news
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Track AXSM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer